Cantor Fitzgerald L. P. Invests $2.97 Million in Abivax SA Sponsored ADR $ABVX

Cantor Fitzgerald L. P. purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, Holdings Channel.com reports. The fund purchased 35,000 shares of the company’s stock, valued at approximately $2,972,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC grew its position in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after buying an additional 369 shares during the period. First Horizon Corp acquired a new stake in shares of Abivax during the 3rd quarter valued at approximately $36,000. Bank of America Corp DE lifted its position in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Hantz Financial Services Inc. purchased a new position in Abivax in the 3rd quarter valued at approximately $52,000. Finally, Cubist Systematic Strategies LLC raised its holdings in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Ratings Changes

ABVX has been the topic of several research reports. Morgan Stanley upped their target price on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Truist Financial set a $140.00 price target on Abivax in a research note on Monday, November 24th. BTIG Research reissued a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Wednesday, February 25th. Citigroup restated a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Finally, Piper Sandler restated an “overweight” rating and set a $142.00 target price on shares of Abivax in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Abivax has a consensus rating of “Moderate Buy” and an average target price of $136.69.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $123.99 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The business’s fifty day moving average price is $119.08 and its two-hundred day moving average price is $109.81. The stock has a market cap of $9.80 billion, a PE ratio of -29.66 and a beta of 1.00. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.